Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal Cancer

by Vandana Singh, Benzinga Editor

May 24, 2021 8:21 AM | 27 seconds read | Make a Comment

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) in combination with Yervoy (ipilimumab), a subset of metastatic colorectal cancer (mCRC).
The recommendation covers the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC after prior fluoropyrimidine-based combination chemotherapy.
The opinion was based on data from the Phase 2 CheckMate -142 trial.
Price Action: BMY shares closed at $67.05 on Friday.

Posted In: Biotech News Health Care FDA General Briefs colorectal cancer european medical agency

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.